COVID-19 patients with a poor outcome in the acute stage of the disease demonstrated higher percentages of CD19+CD5+ and CD19+CD5− cells in relation to both the control values and the values observed in patients with a favorable disease outcome (Figure 4E,F). The gene discussed is CD19; the disease is COVID-19.